Xu B - Search Results

1

The prognostic value of systemic immune-inflammation index in patients with unresectable hepatocellular carcinoma treated with immune-based therapy.

He T, Xu B, Wang LN, Wang ZY, Shi HC, Zhong CJ, Zhu XD, Shen YH, Zhou J, Fan J, Sun HC, Hu B, Huang C. He T, et al. Among authors: xu b. Biomark Res. 2025 Jan 14;13(1):10. doi: 10.1186/s40364-024-00722-6. Biomark Res. 2025. PMID: 39806475 Free PMC article.

2

A prospective study of the effect of terlipressin on portal vein pressure and clinical outcomes after hepatectomy: A pilot study.

Li XL, Zhu XD, Xiao N, Liu XF, Xu B, Shi GM, Huang C, Shen YH, Cai JB, Zhou J, Fan J, Sun HC. Li XL, et al. Among authors: xu b. Surgery. 2020 Jun;167(6):926-932. doi: 10.1016/j.surg.2020.01.013. Epub 2020 Feb 26. Surgery. 2020. PMID: 32113581 Clinical Trial.

3

NT5DC2 promotes tumor cell proliferation by stabilizing EGFR in hepatocellular carcinoma.

Li KS, Zhu XD, Liu HD, Zhang SZ, Li XL, Xiao N, Liu XF, Xu B, Lei M, Zhang YY, Shi WK, Cao MQ, Xu YF, Tang ZY, Sun HC. Li KS, et al. Among authors: xu yf, xu b. Cell Death Dis. 2020 May 7;11(5):335. doi: 10.1038/s41419-020-2549-2. Cell Death Dis. 2020. PMID: 32382041 Free PMC article.

4

CD74⁺ macrophages are associated with favorable prognosis and immune contexture in hepatocellular carcinoma.

Xiao N, Li K, Zhu X, Xu B, Liu X, Lei M, Sun HC. Xiao N, et al. Among authors: xu b. Cancer Immunol Immunother. 2022 Jan;71(1):57-69. doi: 10.1007/s00262-021-02962-z. Epub 2021 May 19. Cancer Immunol Immunother. 2022. PMID: 34009409 Free PMC article.

5

Blocking siglec-10^hi tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma.

Xiao N, Zhu X, Li K, Chen Y, Liu X, Xu B, Lei M, Xu J, Sun HC. Xiao N, et al. Among authors: xu b, xu j. Exp Hematol Oncol. 2021 Jun 10;10(1):36. doi: 10.1186/s40164-021-00230-5. Exp Hematol Oncol. 2021. PMID: 34112250 Free PMC article.

6

Development and Validation of a Nomogram Based on Perioperative Factors to Predict Post-hepatectomy Liver Failure.

Xu B, Li XL, Ye F, Zhu XD, Shen YH, Huang C, Zhou J, Fan J, Chen YJ, Sun HC. Xu B, et al. J Clin Transl Hepatol. 2021 Jun 28;9(3):291-300. doi: 10.14218/JCTH.2021.00013. Epub 2021 Mar 15. J Clin Transl Hepatol. 2021. PMID: 34221915 Free PMC article.

7

Camrelizumab: an investigational agent for hepatocellular carcinoma.

Xu B, Sun HC. Xu B, et al. Expert Opin Investig Drugs. 2022 Apr;31(4):337-346. doi: 10.1080/13543784.2022.2022121. Epub 2021 Dec 28. Expert Opin Investig Drugs. 2022. PMID: 34937475

8

Peripheral naïve CD8⁺ T cells as a predictive biomarker of response to lenvatinib plus an anti-PD-1 antibody in advanced hepatocellular carcinoma: a biomarker study.

Huang C, Xu B, Zhu XD, Shen YH, Li ML, Zhu JJ, Zhou J, Fan J, Sun HC. Huang C, et al. Among authors: xu b. Cancer Commun (Lond). 2022 Nov;42(11):1226-1230. doi: 10.1002/cac2.12350. Epub 2022 Aug 22. Cancer Commun (Lond). 2022. PMID: 35994567 Free PMC article. No abstract available.

9

Criteria for identifying potentially resectable patients with initially oncologically unresectable hepatocellular carcinoma before treatment with lenvatinib plus an anti-PD-1 antibody.

Xu B, Zhu XD, Shen YH, Zhu JJ, Liu J, Li ML, Tang PW, Zhou J, Fan J, Sun HC, Huang C. Xu B, et al. Front Immunol. 2022 Nov 25;13:1016736. doi: 10.3389/fimmu.2022.1016736. eCollection 2022. Front Immunol. 2022. PMID: 36505445 Free PMC article.

10

[No title available]

[No authors listed] [No authors listed] PMID: 36869918

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

18,080 results

Search Page

Filters